#KnowledgeByte: #Pancreatic #Cancer is a leading cause of cancer-related mortality worldwide.
Recent research by Spanish Scientist Mariano Barbacid has yielded promising breakthroughs in laboratory settings and clinical trials.
https://knowledgezone.co.in/posts/Cure-for-pancreatic-cancer-in-sight-697d9e576d67746ca5d5d1be
UCLA scientists have made a significant breakthrough in the fight against triple-negative breast cancer with the discovery of a super-immunotherapy. This revolutionary treatment uses CAR-NKT cells to attack multiple tumor cell antigens, offering new hope for patients with this aggressive form of breast cancer. The CAR-NKT cells can be mass-produced from donated stem cells and stored for immediate use, making it a promising treatment option for those with triple-negative breast cancer.
0 likes, 0 comments - drhowardsmithreports on October 5, 2025: "Pancreatic Cancer Drug University of Cincinnati oncologists have developed a drug that stops pancreatic cancer from suppressing the anti-tumor immunity that threatens to eradicate it. Using a pre-clinical mouse pancreatic cancer model, the researchers pinpointed that the protein Hsp70 is produced by the cancer cells to defuse the anti-cancer immune response. Their next step was to find an antidote Hp70. That they did by developing the rescue agent SapC-DOPG. This drug adheres to pancreatic cancer cells, inhibits Hsp70, and destroys the tumor’s shield against killer T lymphocytes. The next step is to bring this rescue compound and others like it into the clinic for an array of trials. Hopefully, they will confirm the effectiveness of this concept and join the fight against this dread disease…..someday soon. #pancreatic #cancer #immunotherapy #hsp70 #sapCDOPG".
0 likes, 0 comments - drhowardsmithreports on August 26, 2025: "A Vaccine Against Pancreatic Cancer An already FDA-approved cancer vaccine was spectacularly effective in controlling pancreatic cancers that carry the KRAS markers. A multi-center phase 1 study, helmed by oncologists at New York’s Sloan Kettering and Texas’ MD Anderson, studied the vaccine labeled ELI-002 developed by Boston’s Elicio Therapeutics. The results demonstrated that the vaccine can trigger a vigorous killer T cell response to this KRAS marker carried by 88% of pancreatic cancers. They also showed that 65% of patients who mounted this T cell response to the vaccine enjoyed no radiographic progression of their cancers. Even more exciting, five of the sewpatients were free of tumor relapse without any subsequent therapy following the vaccine. When the study ended after nearly 20 months, these excellent responders were all alive without evidence of cancer recurrence. In contrast, the untreated controls developed cancer relapses in an average of 3 months and only survived an average of 15 months. Unlike most cancer vaccines that are custom produced for each patient’s tumor, ELI-002 can be mass produced making it readily available for administration and less expensive. A phase 2 trial of the vaccine is already in progress. Pancreatic cancer is one of the deadliest cancers, with only about 13% of patients surviving five years after diagnosis and recurrence rates as high as 80% within two years of surgery. Hopefully, this vaccine immunotherapy will help change those dismal statistics. https://www.nature.com/articles/s41591-025-03876-4 #cancer #pancreatic #vaccine #ELI002 #elicio #iommunotherapy".
The findings, published in Nature Medicine, show that the vaccine can trigger powerful and lasting immune responses and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations.
Kpop News Hub
Knowledge Zone
Scientific Frontline
Howard Smith MD, AM
beSpacific
EssJay PURPLE PURPOSE
David Basanta